Elizabeth Rajan, M.D. mayoclinic.org/biographies/ra…

When they are done with Diddy they will remove their next puppet that has their secrets. I don’t think anyone is ready for what is coming.

$RVPH Based on the available information, Grok 2 would lean towards brilaroxazine as potentially the better choice for a broader patient population due to: Favorable Safety Profile: Brilaroxazine's lower incidence of weight gain, metabolic changes, and extrapyramidal symptoms

$rvph A Pfizer-RVPH team-up in Q2 2025, pre-RECOVER-2, could value RVPH at $2-$4 billion ($50-$100/share), scaling to $6-$8 billion post-success, aligning with Saxena and Tang’s apparent urgency. Brilaroxazine re-energizes Pfizer’s CNS play, outpacing Cobenfy on tolerability

$rvpt $lax_bhat Go ask Grok or Cht to do a deep drive efficacy comparison between Brilaroxazine and KarXT… amazing results for our little engine that should could and will

$rvph. $lax_bhat Go ask Grok or Cht to do a deep drive efficacy comparison between Brilaroxazine and KarXT… amazing results for our little engine that should could and will

$rvph Kinda feel like those 300 people on the 10 hour Air India flight to India and 11 of the 12 toilets are clogged. At least the President from the Airline offered refunds… crazy times bring crazy events. I’m still a believer in LAX, PARAG & Tang

$rvph FACT! SIRS Conference Brilaroxazine Phase 3 OLE March 30th 2025 10:30 a.m.

$rvph KEEP THIS IN Perspective! RVPH’s vocal biomarkers could be huge in the schizophrenia market, thrusting it to the technological forefront with $4–$8B peak sales potential (NPV $2–$2.8B) and a $1–$2B buyout ($28–$58/share) if OLE excels. It’s a market-disrupting edge no one

$rvph

Tariffs or Tear offs 😍

$rvph. . Results from ASCP Meeting Excellent result Abstract Background Brilaroxazine (RP5063), a multimodal, serotonin-dopamine neurotransmitter signaling modulator, possesses high affinity (Ki, <6nM) and selectivity for key serotonin receptors 5-HT1A/2A/2B/7, partial

$RVPH Grok Conclusion The 2025 ASCP abstract's OLE study reinforces and extends the Phase 3 RECOVER trial's findings, showing sustained, dose-dependent efficacy (PANSS reductions -15.2 to -20.8 points at 52 weeks vs. -23.9 for 50 mg at 4 weeks from baseline), excellent safety,

$rvph. Where is Peter Wu

$NAK Has anyone ever seen the amount of copper that is required to build a data center. Go visit a facility that manufacturers the electrical power panels for these hugh facilities. We do not have enough CU to sustain the growth of these data centers Go Get the CU